Literature DB >> 24876813

Stroke thrombolysis at 5.5 hours based on computed tomography perfusion.

Ramesh Sahathevan1, Shahrul Azmin1, Sivakumar Palaniappan1, Wan Yahya Nafisah1, Hui Jan Tan1, Mohamed Ibrahim Norlinah1, Mukari Shahizon2.   

Abstract

A young man was admitted with sudden onset of right-sided weakness. He was assessed in the emergency department, and an immediate computed tomography (CT) perfusion study of the brain was arranged, which showed a left middle cerebral artery territory infarct with occlusion of the M1 segment. There was a significant penumbra measuring approximately 50% of the arterial territory. By the time his assessment was completed, it was 5.5 hours from the onset of symptoms. He was nonetheless administered intravenous recombinant tissue plasminogen activator (rtPA) based on the significant penumbra. He was discharged from the hospital after one week with significant residual deficit. At 2 months clinic follow-up, he showed almost complete recovery with a Modified Rankin Score of 1. We hope to demonstrate that a significant penumbra is an important determinant for good neurological recovery and outcome following stroke thrombolysis, even when patients present outside the 4.5 hours onset-to-treatment time window.

Entities:  

Keywords:  computed tomography; developing countries; perfusion; rtPA; stroke; thrombolysis

Year:  2014        PMID: 24876813      PMCID: PMC4028577     

Source DB:  PubMed          Journal:  Malays J Med Sci        ISSN: 1394-195X


  10 in total

1.  Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials.

Authors:  Kennedy R Lees; Erich Bluhmki; Rüdiger von Kummer; Thomas G Brott; Danilo Toni; James C Grotta; Gregory W Albers; Markku Kaste; John R Marler; Scott A Hamilton; Barbara C Tilley; Stephen M Davis; Geoffrey A Donnan; Werner Hacke; Kathryn Allen; Jochen Mau; Dieter Meier; Gregory del Zoppo; D A De Silva; K S Butcher; M W Parsons; P A Barber; C Levi; C Bladin; G Byrnes
Journal:  Lancet       Date:  2010-05-15       Impact factor: 79.321

2.  MRI profile and response to endovascular reperfusion after stroke (DEFUSE 2): a prospective cohort study.

Authors:  Maarten G Lansberg; Matus Straka; Stephanie Kemp; Michael Mlynash; Lawrence R Wechsler; Tudor G Jovin; Michael J Wilder; Helmi L Lutsep; Todd J Czartoski; Richard A Bernstein; Cherylee W J Chang; Steven Warach; Franz Fazekas; Manabu Inoue; Aaryani Tipirneni; Scott A Hamilton; Greg Zaharchuk; Michael P Marks; Roland Bammer; Gregory W Albers
Journal:  Lancet Neurol       Date:  2012-09-04       Impact factor: 44.182

3.  A multicentre, randomized, double-blinded, placebo-controlled Phase III study to investigate EXtending the time for Thrombolysis in Emergency Neurological Deficits (EXTEND).

Authors:  Henry Ma; Mark W Parsons; Soren Christensen; Bruce C V Campbell; Leonid Churilov; Alan Connelly; Bernard Yan; Chris Bladin; Than Phan; Alan P Barber; Stephen Read; Graeme J Hankey; Romesh Markus; Tissa Wijeratne; R Grimley; N Mahant; Tim Kleinig; John Sturm; A Lee; D Blacker; Richard Gerraty; M Krause; P M Desmond; S J McBride; Leanne Carey; David W Howells; C Y Hsu; Stephen M Davis; Geoffrey A Donnan
Journal:  Int J Stroke       Date:  2012-01       Impact factor: 5.266

4.  Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke.

Authors:  Werner Hacke; Markku Kaste; Erich Bluhmki; Miroslav Brozman; Antoni Dávalos; Donata Guidetti; Vincent Larrue; Kennedy R Lees; Zakaria Medeghri; Thomas Machnig; Dietmar Schneider; Rüdiger von Kummer; Nils Wahlgren; Danilo Toni
Journal:  N Engl J Med       Date:  2008-09-25       Impact factor: 91.245

5.  Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial.

Authors:  Stephen M Davis; Geoffrey A Donnan; Mark W Parsons; Christopher Levi; Kenneth S Butcher; Andre Peeters; P Alan Barber; Christopher Bladin; Deidre A De Silva; Graham Byrnes; Jonathan B Chalk; John N Fink; Thomas E Kimber; David Schultz; Peter J Hand; Judith Frayne; Graeme Hankey; Keith Muir; Richard Gerraty; Brian M Tress; Patricia M Desmond
Journal:  Lancet Neurol       Date:  2008-02-28       Impact factor: 44.182

6.  CT perfusion improves diagnostic accuracy and confidence in acute ischaemic stroke.

Authors:  Bruce C V Campbell; Louise Weir; Patricia M Desmond; Hans T H Tu; Peter J Hand; Bernard Yan; Geoffrey A Donnan; Mark W Parsons; Stephen M Davis
Journal:  J Neurol Neurosurg Psychiatry       Date:  2013-01-25       Impact factor: 10.154

7.  National US estimates of recombinant tissue plasminogen activator use: ICD-9 codes substantially underestimate.

Authors:  Dawn Kleindorfer; Christopher J Lindsell; Lawrence Brass; Walter Koroshetz; Joseph P Broderick
Journal:  Stroke       Date:  2008-01-31       Impact factor: 7.914

8.  MRI-based and CT-based thrombolytic therapy in acute stroke within and beyond established time windows: an analysis of 1210 patients.

Authors:  Peter D Schellinger; Götz Thomalla; Jens Fiehler; Martin Köhrmann; Carlos A Molina; Tobias Neumann-Haefelin; Marc Ribo; Oliver C Singer; Olivier Zaro-Weber; Jan Sobesky
Journal:  Stroke       Date:  2007-08-16       Impact factor: 7.914

9.  The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial.

Authors:  Peter Sandercock; Joanna M Wardlaw; Richard I Lindley; Martin Dennis; Geoff Cohen; Gordon Murray; Karen Innes; Graham Venables; Anna Czlonkowska; Adam Kobayashi; Stefano Ricci; Veronica Murray; Eivind Berge; Karsten Bruins Slot; Graeme J Hankey; Manuel Correia; Andre Peeters; Karl Matz; Phillippe Lyrer; Gord Gubitz; Stephen J Phillips; Antonio Arauz
Journal:  Lancet       Date:  2012-05-23       Impact factor: 79.321

10.  Safety and clinical outcome of thrombolysis in ischaemic stroke using a perfusion CT mismatch between 3 and 6 hours.

Authors:  Laszlo K Sztriha; Dulka Manawadu; Jozef Jarosz; Jeff Keep; Lalit Kalra
Journal:  PLoS One       Date:  2011-10-10       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.